cb-5083
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02223598)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ATAD2B inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc2c(C(N)=O)cccc2n1-c1nc2c(c(NCc3ccccc3)n1)COCC2- Mol. weight
- 413.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3747513 ↗
Also known as
- cb-5083
- cb-5083
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02243917 | Phase 1 | Oct 1, 2014 | Cleave Biosciences, Inc. |
| NCT02223598 | Phase 1 | Jul 1, 2014 | Cleave Biosciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cleave Biosciences, Inc. | For profit | 2 | 2 | 1 | 2014 |
1 organizations
Page 1 / 1